Vanda Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.ACAD · PharmaceuticalsSan Diego, United States

69% matchPublicAI 9/100 ▼Green 0/100 ▼

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Idorsia Pharmaceuticals LtdPharmaceuticals, BiotechSwitzerland

68% match

Idorsia Pharmaceuticals Ltd is a biopharmaceutical company that conducts drug discovery, clinical development, and commercial operations to provide transformative treatments for patients. The company focuses on researching and developing therapeutic products and vaccines targeting conditions such as insomnia, hypertension, and Fabry disease.

Supernus Pharmaceuticals, Inc.0LB2 · PharmaceuticalsRockville, United States

66% matchPublic

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medications addresses a range of CNS conditions. These include Trokendi XR, an extended-release formulation of topiramate used for managing epilepsy and preventing migraine headaches, and Oxtellar XR, an extended-release oxcarbazepine prescribed as a standalone treatment for partial-onset epileptic seizures in individuals aged 6 to 17 and adults. Another key offering is Qelbree, a selective norepinephrine reuptake inhibitor specifically designed for pediatric patients (ages 6 to 17) suffering from attention-deficit hyperactivity disorder (ADHD). For Parkinson's Disease (PD), Supernus provides APOKYN for acute intermittent treatment of 'off' episodes or hypomobility in advanced stages, XADAGO to aid patients on levodopa/carbidopa experiencing 'off' periods, and GOCOVRI to treat dyskinesia. Osmolex ER is also available for PD and drug-induced extrapyramidal reactions in adults. Furthermore, the company commercializes MYOBLOC, a Type B toxin, for treating cervical dystonia and sialorrhea in adult patients. Beyond its commercialized therapies, Supernus maintains an active pipeline of investigational treatments. This includes Qelbree (SPN-812), having finished Phase III trials for ADHD, and SPN-830, a late-stage drug/device combination aiming to prevent 'off' episodes in Parkinson's patients. Also in development are SPN-817, a novel compound undergoing Phase I clinical trials for severe epilepsy, and SPN-820, currently in Phase II for refractory depression. Additionally, two preclinical-stage candidates, SPN-443 and SPN-446, are being explored for other CNS indications. The distribution of these products occurs via pharmaceutical wholesalers, specialized pharmacies, and various distributors. Established in 2005, the company maintains its principal office in Rockville, Maryland.

HLS Therapeutics Inc.HLS · PharmaceuticalsEtobicoke, Canada

66% matchPublic

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

Vistagen Therapeutics, Inc.VTGN · PharmaceuticalsSouth San Francisco, United States

66% matchPublic

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.